PTC Therapeutics Inc (PTCT) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of PTC Therapeutics Inc stock $196, price $65.44, upside +200.0%, quality 67 out of 100. Rating: strongly undervalued. Calculated from audited financials with 21 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 9, 2026.
How to read this chart
60‑month range $18.07 – $89.55 · fair‑value band $96.29 – $403.35 · the $65.44 price screens below the $196.32 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 9, 2026.
Follow PTC Therapeutics in your weekly email
Every Wednesday you see whether PTC Therapeutics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally.
Show moreShow less
The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.
Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and inflammation and ferroptosis platforms, including vatiquinone to treat Friedreich's ataxia.
The company distributes its products through third-party distributors.
It has collaborations with F. Hoffman-La Roche Ltd., Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program.
It markets Upstaza, a gene therapy with the brand name Kebilidi in the United States. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in Warren, New Jersey.
Stock analysis
PTC Therapeutics Inc (PTCT) currently trades at $65.44, while our model-based Fair Value estimate is $196.32, implying the stock looks roughly 67% undervalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of $380.01 per share, and 21 of the 21 models we run sit above the $65.44 price.
Bear case: the Economic Profit group reads lowest at $136.27, and 0 of the 21 models stay below the price. Data coverage for this calculation is low.
Scenario range: $96.29 (bear) to $403.35 (bull), the price of $65.44 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 67/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
PTC Therapeutics Inc reported revenue of $1.7B in FY2025 versus $539M in FY2021, a compound +33.9%/yr. Reported net income was $683M in FY2025.
Key figures
Market cap $6.0B Mid · P/S ratio 4.96 · EPS (TTM) $−0.6500 · Net margin −3.8% · Return on equity −7,740% · Return on assets (EBIT) −11.4% (5-year average) · Operating margin 41.3% · Revenue (TTM) $1.0B.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 67 out of 100 (low confidence).
What moves the price
The share trades about 27% below its 52-week high and 10% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at 200%, PTCT screens cheaper than that median.
Fair Value models
Bear$96.29Fair Value $196.32Bull$403.35
Price $65.44 · Upside +200.0%
Capped: our models arrive at a very high value here. We deliberately show a more cautious Fair Value.
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
In the last 6 months, 9 officers or directors sold shares worth $24.8M and none bought.
SaleMichael SchmertzlerDirector6× since Aug 19, 2026: 95,000 shares, avg. $69.69$6.6MOct 14, 202610b5-1 plan
SaleMark Elliott BouldingEXEC. VP AND CLO14× since Nov 17, 2025: 56,192 shares, avg. $75.60$4.2MOct 9, 202610b5-1 plan
SaleGlenn Steele Jr Md PhdDirector2× since Jan 2, 2026: 24,000 shares, avg. $70.76$1.7MSep 30, 202610b5-1 plan
SaleMatthew B. KleinCHIEF EXECUTIVE OFFICER, Director9× since Dec 2, 2025: 57,943 shares, avg. $72.83$4.2MAug 4, 202610b5-1 plan
SalePierre GravierCHIEF FINANCIAL OFFICER3× since Jan 6, 2026: 8,625 shares, avg. $75.69$652,864Jul 14, 202610b5-1 plan
SaleNeil Gregory AlmsteadCHIEF TECHNICAL OPS OFFICER12× since Nov 24, 2025: 277,364 shares, avg. $80.60$22.4MJul 9, 202610b5-1 plan
SaleMary L. SmithDirector15,834 shares at $90.00$1.4MJul 9, 202610b5-1 plan
SaleChristine Marie UtterSVP, CHIEF ACCOUNTING OFFICER4× since Jan 6, 2026: 25,830 shares, avg. $75.16$1.9MJun 17, 202610b5-1 plan
SaleEric PauwelsCHIEF BUSINESS OFFICER6× since Dec 17, 2025: 98,785 shares, avg. $75.69$7.5MJun 10, 202610b5-1 plan
SaleLee Scott GoldenEVP & CHIEF MEDICAL OFFICER5× since Jan 6, 2026: 16,161 shares, avg. $66.92$1.1MApr 2, 202610b5-1 plan
Plus 3 more entries from the last 12 months.
Plus 17 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.
Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.82/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+114.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+35.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+35.4%
Start year 2020 (pandemic). Over 10 years: +47.0% a year
Revenue growth 21 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+39.4%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−113.4% (2020) → 49.5% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: no profitable base year
not computed
Growth Forecast
Price in line with expectations
The price assumes less growth than the company has delivered so far and about what analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+2.6%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+0.0%
Yearly sales growth analysts expect, extended to five years.
Calculated on free cash flow for fiscal year 2025. Over the last twelve months it was negative, so the figure above is uncertain.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +0.2% a year for the price and −2.3% for the forecasts.
News mood ⓘNews mood, the average tone of recent news (92 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.Positive
Recent news coverage is more positive than average.
AI conclusion: The business benefits from strong early uptake of its newer PKU therapy along with gene therapy pipeline optionality, yet suffers from eroding contributions of legacy DMD treatments.
Main risk: Regulators could deny or withdraw marketing authorisations for Translarna or pipeline candidates such as vatiquinone due to insufficient efficacy data, reducing revenues from those products.
Bull case: By securing approvals for newer assets such as sepiapterin in PKU and advancing gene-therapy programmes through partnerships the company could replace declining legacy revenues and expand its rare-disease portfolio.
Bear case: If regulatory setbacks persist and patent expiries trigger generic or rival competition without sufficient new-product offsets the company might face sustained revenue erosion and need deeper cost restructuring or further asset deals.
PTC's established treatments for Duchenne muscular dystrophy continue to face generic competition and regulatory setbacks that erode their contribution. At the same time the newer PKU therapy shows strong early uptake and the pipeline holds further optionality in gene therapy. Our models see the shares as undervalued. Will the growth from the newer assets fully offset the legacy declines or will the business need to adapt its cost base and deal activity more aggressively?
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 558 stocks
Beats the industry median on 8/10 measures
Overall it ranks above its industry peers.
Valuation
Quality Score67 · Top 25%
Fair Value upside+200.0% · Top 25%
Profitability
Return on equity (12 months)Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Return on assets23.5% · Top 25%
Net margin (12 months)−3.8% · Below median
Operating margin (12 months)41.3% · Top 25%
Growth and dividend
Revenue growth (quarter YoY)101.5% · Top 25%
Balance sheet
Debt / equityNegative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Valuation Multiplesvs Biotechnology median · lower = cheaper
P/BNegative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is PTC Therapeutics Inc (PTCT) overvalued or undervalued?
As of Nov 9, 2026, our model estimates a fair value of $196.32 versus a price of $65.44, about +200% upside (undervalued).
What is the fair value of PTCT?
Our model-based fair value for PTC Therapeutics Inc is $196.32 (as of Nov 9, 2026), built from audited fundamentals. The current price: $65.44.
What is the quality score of PTCT?
PTC Therapeutics Inc has a Quality Score of 67/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for PTC Therapeutics Inc (PTCT)?
Our model-based price target is the fair value of $196.32 (as of Nov 9, 2026) from 21 valuation models. Cautious scenario $96.29, optimistic scenario $403.35. It is a calculation from audited fundamentals, not an analyst target.
What is the PTC Therapeutics Inc stock forecast for 2026?
Our models put fair value at $196.32, about +200% upside versus a price of $65.44 (undervalued). Cautious scenario $96.29, optimistic scenario $403.35. The calculation is refreshed regularly with new filings.
What is the revenue of PTC Therapeutics Inc (PTCT)?
PTC Therapeutics Inc reported trailing-twelve-month revenue of about $1.0B (latest available figure, as of Nov 9, 2026).
What growth is priced into PTC Therapeutics Inc (PTCT)?
For today's price to be fair in a discounted-cash-flow model, PTC Therapeutics Inc would have to grow free cash flow by +2.6 % per year for five years (discount rate 8.5 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +35.4 % per year. Calculated on free cash flow for fiscal year 2025. Over the last twelve months it was negative, so the figure above is uncertain. As of Nov 9, 2026.
What discount rate (WACC) does the fair value of PTCT use?
Our models discount PTC Therapeutics Inc at 8.5 %: a base by market capitalisation (mid), damped by beta 0.49, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For PTC Therapeutics Inc that is +2.6 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (8.5 %) and the same formula as our fair value.
How much growth has PTC Therapeutics Inc (PTCT) delivered so far?
Over the past 5 years revenue at PTC Therapeutics Inc grew +35.4 % a year. The price currently implies free-cash-flow growth of +2.6 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of PTC Therapeutics Inc (PTCT) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into PTC Therapeutics Inc (+2.6 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of PTC Therapeutics Inc (PTCT)?
The free-cash-flow yield on the price is 6.83 % in the last fiscal year (free cash flow was negative over the last twelve months): that much free cash flow PTC Therapeutics Inc produces per unit of market value. When it exceeds the discount rate of our models (8.5 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of PTC Therapeutics Inc (PTCT)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For PTC Therapeutics Inc it is $196.32 per share (as of Nov 9, 2026), against a price of $65.44. It is the blended result of 21 valuation models in 6 families (DCF Models, Earnings-Based, Multiples, Growth DCF, Economic Profit, Growth Earnings).
Is PTC Therapeutics Inc stock overvalued or undervalued in 2026?
As of Nov 9, 2026, PTCT trades below its calculated fair value: price $65.44, fair value $196.32, a gap of about +200% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of PTCT?
No. The price is what the market pays today ($65.44); the fair value is what the company's own numbers justify ($196.32). For PTC Therapeutics Inc the two are $130.88 per share apart. That gap is exactly why we show both numbers side by side.
How much is PTC Therapeutics Inc worth?
The market values PTC Therapeutics Inc at about $6.0B (market capitalisation, as of Nov 9, 2026). Per share that is $65.44; our models calculate a fair value of $196.32 per share.
What do the bullish and bearish scenarios say about PTCT?
Our models span a range for PTC Therapeutics Inc: cautious scenario $96.29, base $196.32, optimistic $403.35 per share (as of Nov 9, 2026, price $65.44). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the PEG ratio of PTCT?
The PEG ratio of PTC Therapeutics Inc is 0.81 (P/E divided by earnings growth, as of Nov 9, 2026). That is below 1, so growth is priced more cheaply than the earnings multiple alone suggests.
How solid is the balance sheet of PTC Therapeutics Inc (PTCT)?
Balance-sheet figures for PTC Therapeutics Inc (as of Nov 9, 2026): negative equity, so no return on equity and no debt-to-equity ratio. They feed the Quality Score of 67/100, which measures business quality independently of the share price.
How far is PTCT from its 52-week high?
PTC Therapeutics Inc trades at $65.44, about 27% below its 52-week high of $89.55 and 10% above the low of $59.24 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of $196.32 is for.
Which stocks are comparable to PTC Therapeutics Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is PTC Therapeutics Inc stock attractive at the current price?
The data as of Nov 9, 2026: price $65.44, calculated fair value $196.32 (+200%), Quality Score 67/100, from 21 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of PTCT calculated?
We run PTC Therapeutics Inc through 21 models from 6 families: DCF Models, Earnings-Based, Multiples, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of $196.32 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. PTC Therapeutics Inc currently trades 67% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of PTC Therapeutics Inc (PTCT)?
The closing price on Nov 6, 2026 was $65.44. Our model-based fair value is $196.32, about +200% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with PTC Therapeutics Inc right now?
The price is below even our cautious bear case ($96.29). The market is more pessimistic than our downside scenario. The model range is unusually wide ($96.29 to $403.35). The outcome hinges heavily on assumptions, so read the point estimate with caution. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid quality (67/100) at a price below fair value, the discount is the argument here, not the business quality.
Key figures of PTC Therapeutics Inc
How large is the market capitalisation of PTC Therapeutics Inc (PTCT)?
The market capitalisation of PTC Therapeutics Inc is $6.0B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of PTC Therapeutics Inc (PTCT)?
The price-to-sales ratio of PTC Therapeutics Inc is 4.96 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of PTC Therapeutics Inc (PTCT)?
Earnings per share at PTC Therapeutics Inc are $−0.6500. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of PTC Therapeutics Inc (PTCT)?
The net margin of PTC Therapeutics Inc is −3.8% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of PTC Therapeutics Inc (PTCT)?
The return on equity (ROE) of PTC Therapeutics Inc is −7,740% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of PTC Therapeutics Inc (PTCT)?
On an EBIT basis the return on assets of PTC Therapeutics Inc is −11.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of PTC Therapeutics Inc (PTCT)?
The operating margin of PTC Therapeutics Inc is 41.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at PTC Therapeutics Inc (PTCT)?
Revenue at PTC Therapeutics Inc is growing +102% versus a year earlier (3y avg +35.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much net cash does PTC Therapeutics Inc (PTCT) hold?
PTC Therapeutics Inc holds more cash than debt, $492M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch PTC Therapeutics Inc in the live analysis
One click puts PTC Therapeutics Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 9, 2026